These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 38673626)

  • 1. Are There Sex-Related Differences in the Effectiveness of Janus Kinase Inhibitors in Rheumatoid Arthritis Patients?
    Martinez-Molina C; Feliu A; Park HS; Juanes A; Diaz-Torne C; Vidal S; Corominas H
    J Clin Med; 2024 Apr; 13(8):. PubMed ID: 38673626
    [No Abstract]   [Full Text] [Related]  

  • 2. Relative Remission and Low Disease Activity Rates of Tofacitinib, Baricitinib, Upadacitinib, and Filgotinib versus Methotrexate in Patients with Disease-Modifying Antirheumatic Drug-Naive Rheumatoid Arthritis.
    Lee YH; Song GG
    Pharmacology; 2023; 108(6):589-598. PubMed ID: 37591216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relative remission rates of Janus kinase inhibitors in comparison with adalimumab in patients with active rheumatoid arthritis: a network meta-analysis.
    Lee YH; Song GG
    Z Rheumatol; 2024 Feb; 83(Suppl 1):88-96. PubMed ID: 35142908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are all JAK inhibitors for the treatment of rheumatoid arthritis equivalent? An adjusted indirect comparison of the efficacy of tofacitinib, baricitinib, upadacitinib, and filgotinib.
    Vallez-Valero L; Gasó-Gago I; Marcos-Fendian Á; Garrido-Alejos G; Riera-Magallón A; Plaza Diaz A; Martinez-Molina C; Mangues-Bafalluy MA; Corominas H
    Clin Rheumatol; 2023 Dec; 42(12):3225-3235. PubMed ID: 37831336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brief Report: Remission Rates With Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria.
    Smolen JS; Aletaha D; Gruben D; Zwillich SH; Krishnaswami S; Mebus C
    Arthritis Rheumatol; 2017 Apr; 69(4):728-734. PubMed ID: 27907269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences in disease activity measures in patients with rheumatoid arthritis who achieved DAS, SDAI, or CDAI remission but not Boolean remission.
    Aletaha D; Wang X; Zhong S; Florentinus S; Monastiriakos K; Smolen JS
    Semin Arthritis Rheum; 2020 Apr; 50(2):276-284. PubMed ID: 31590930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-Life Comparison of Four JAK Inhibitors in Rheumatoid Arthritis (ELECTRA-
    Benucci M; Li Gobbi F; Damiani A; Russo E; Guiducci S; Manfredi M; Lari B; Grossi V; Infantino M
    J Clin Med; 2024 Mar; 13(6):. PubMed ID: 38542045
    [No Abstract]   [Full Text] [Related]  

  • 8. Association between Hematological Indicesand Disease Activity in Patients with Rheumatoid Arthritis Treated with Janus Kinase Inhibitors for 24 Weeks.
    Choe JY; Kim SK
    Medicina (Kaunas); 2022 Mar; 58(3):. PubMed ID: 35334603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Matching-Adjusted Indirect Comparison of Upadacitinib Versus Tofacitinib in Adults with Moderate-to-Severe Rheumatoid Arthritis.
    Edwards CJ; Sawant R; Garg V; Du EX; Friedman A; Betts KA
    Rheumatol Ther; 2021 Mar; 8(1):167-181. PubMed ID: 33244703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive evaluation of the influence of sex differences on composite disease activity indices for rheumatoid arthritis: results from a nationwide observational cohort study.
    Nishino T; Hashimoto A; Tohma S; Matsui T
    BMC Rheumatol; 2023 Mar; 7(1):4. PubMed ID: 36945056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Visualization of DAS28, SDAI, and CDAI: the magic carpets of rheumatoid arthritis.
    Futó G; Somogyi A; Szekanecz Z
    Clin Rheumatol; 2014 May; 33(5):623-9. PubMed ID: 24599677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How much does Disease Activity Score in 28 joints ESR and CRP calculations underestimate disease activity compared with the Simplified Disease Activity Index?
    Fleischmann R; van der Heijde D; Koenig AS; Pedersen R; Szumski A; Marshall L; Bananis E
    Ann Rheum Dis; 2015 Jun; 74(6):1132-7. PubMed ID: 25143522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tofacitinib versus methotrexate as the first-line disease-modifying antirheumatic drugs in the treatment of rheumatoid arthritis: An open-label randomized controlled trial.
    Khan MM; Ahmed S; Hasan Sajib MK; Morshed AA; Mahbub-Uz-Zaman K; Haq SA
    Int J Rheum Dis; 2023 Sep; 26(9):1729-1736. PubMed ID: 37377385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants.
    Smolen JS; Aletaha D
    Arthritis Rheum; 2011 Jan; 63(1):43-52. PubMed ID: 21204103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A systematic comparison of different composite measures (DAS 28, CDAI, SDAI, and Boolean approach) for determining treatment effects on low disease activity and remission in rheumatoid arthritis.
    Janke K; Kiefer C; McGauran N; Richter B; Krause D; Wieseler B
    BMC Rheumatol; 2022 Dec; 6(1):82. PubMed ID: 36482451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural damage progression in patients with early rheumatoid arthritis treated with methotrexate, baricitinib, or baricitinib plus methotrexate based on clinical response in the phase 3 RA-BEGIN study.
    van der Heijde D; Durez P; Schett G; Naredo E; Østergaard M; Meszaros G; De Leonardis F; de la Torre I; López-Romero P; Schlichting D; Nantz E; Fleischmann R
    Clin Rheumatol; 2018 Sep; 37(9):2381-2390. PubMed ID: 30078086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-World Treatment Patterns and Clinical Outcomes of Baricitinib in Rheumatoid Arthritis Patients in Spain: Results of a Multicenter, Observational Study in Routine Clinical Practice (The ORBIT-RA Study).
    Hernández-Cruz B; Rosas J; Díaz-Torné C; Belzunegui J; García-Vicuña R; Inciarte-Mundo J; Pons A; Millán AM; Jeria-Navarro S; Valero JA; García-Castañeda N; Valero C; Llorente I; Calvo A; Díaz-Cerezo S; Núñez M
    Rheumatol Ther; 2022 Apr; 9(2):589-608. PubMed ID: 35041155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different Biomarkers of Response to Treatment with Selective Jak-1 Inhibitors in Rheumatoid Arthritis.
    Benucci M; Gobbi FL; Fusi P; Damiani A; Russo E; Guiducci S; Manfredi M; Grossi V; Infantino M; Amedei A
    Front Biosci (Landmark Ed); 2023 Aug; 28(8):176. PubMed ID: 37664943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of different Janus kinase inhibitors combined with methotrexate for the treatment of rheumatoid arthritis: a single-center randomized trial.
    Liao X; Huo W; Zeng W; Qin F; Dong F; Wei W; Lei L
    Adv Rheumatol; 2023 Oct; 63(1):50. PubMed ID: 37845778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Efficacy of JAK Inhibitors for Moderate-To-Severe Rheumatoid Arthritis: A Network Meta-Analysis.
    Pope J; Sawant R; Tundia N; Du EX; Qi CZ; Song Y; Tang P; Betts KA
    Adv Ther; 2020 May; 37(5):2356-2372. PubMed ID: 32297280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.